Construction of a retroviral vector production system with the minimum possibility of a homologous recombination

[1]  S. Chang,et al.  Generation of retroviral packaging and producer cell lines for large-scale vector production and clinical application: improved safety and high titer. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  D. Kim,et al.  Improved expression of vascular endothelial growth factor by naked DNA in mouse skeletal muscles: implication for gene therapy of ischemic diseases. , 2000, Biochemical and biophysical research communications.

[3]  Jungkon Kim,et al.  High efficiency retroviral vectors that contain no viral coding sequences , 2000, Gene Therapy.

[4]  A. Miller,et al.  Characterization of recombination events leading to the production of an ecotropic replication-competent retrovirus in a GP+envAM12-derived producer cell line. , 2000, Virology.

[5]  K. Abel,et al.  Design of 5′ Untranslated Sequences in Retroviral Vectors Developed for Medical Use , 1999, Journal of Virology.

[6]  R. Vile,et al.  A Replication-Competent Retrovirus Arising from a Split-Function Packaging Cell Line Was Generated by Recombination Events between the Vector, One of the Packaging Constructs, and Endogenous Retroviral Sequences , 1998, Journal of Virology.

[7]  A. Kingsman,et al.  Minimal Requirement for a Lentivirus Vector Based on Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[8]  P. Robbins,et al.  A simple and rapid method for the determination of recombinant retrovirus titer by G418 selection. , 1996, Gene therapy.

[9]  Y Takeuchi,et al.  High-titer packaging cells producing recombinant retroviruses resistant to human serum , 1995, Journal of virology.

[10]  A. Kingsman,et al.  A transient three-plasmid expression system for the production of high titer retroviral vectors. , 1995, Nucleic acids research.

[11]  W. Anderson,et al.  Characterization of a replication-competent retrovirus resulting from recombination of packaging and vector sequences. , 1994, Human gene therapy.

[12]  T. Dull,et al.  kat: A high-efficiency retroviral transduction system for primary human T lymphocytes , 1994 .

[13]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[14]  G. Nolan,et al.  Production of high-titer helper-free retroviruses by transient transfection. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Raffeld,et al.  Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer , 1992, The Journal of experimental medicine.

[16]  K. Cornetta,et al.  Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. , 1990, Human gene therapy.

[17]  Miller Ad,et al.  Improved Retroviral Vectors for Gene Transfer and Expression , 1989 .

[18]  A. Miller,et al.  Improved retroviral vectors for gene transfer and expression. , 1989, BioTechniques.

[19]  R. Mulligan,et al.  Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[20]  S. Goff,et al.  A safe packaging line for gene transfer: separating viral genes on two different plasmids , 1988, Journal of virology.

[21]  R. Lerner,et al.  Nucleotide sequence of Moloney murine leukaemia virus , 1981, Nature.